Continue Current Insulin Regimen
You should continue the current insulin regimen of glargine 10 units daily plus metformin 850 mg twice daily. This patient presented with DKA—a severe hyperglycemic crisis requiring insulin therapy—and basal insulin must be maintained to prevent recurrence 1.
Why Insulin Must Be Continued
This patient's DKA presentation indicates severe insulin deficiency requiring immediate and ongoing insulin therapy. The 2022 AACE guidelines explicitly state that basal insulin along with noninsulin therapy is recommended when there are significant signs or symptoms of hyperglycemia, especially including catabolism (e.g., weight loss) or very high A1C >10% or blood glucose levels ≥300 mg/dL 1. DKA itself represents the most extreme manifestation of this—she had ketoacidosis requiring hospitalization.
The negative autoantibodies do not change the immediate management. While they suggest type 2 diabetes rather than latent autoimmune diabetes, the severity of her presentation (DKA) mandates insulin therapy regardless of diabetes type 1.
Metformin should be continued alongside insulin per AACE guidelines: "Persons with T2D who start on metformin should continue it unless intolerance or contraindications occur. When intensification of antihyperglycemic treatment is needed, other agents should be added to metformin" 1.
Why NOT to Increase Metformin Alone
Increasing metformin dose without maintaining insulin would be dangerous:
Metformin alone cannot prevent DKA recurrence. The maximum metformin dose is 2000-2550 mg daily 2, and she's already on 1700 mg daily. Even at maximum dose, metformin provides insufficient glycemic control for someone who just had DKA.
Metformin does not replace insulin in severe hyperglycemia. The AACE algorithm clearly shows that insulin is required when A1C >10% or glucose >300 mg/dL with symptomatic hyperglycemia 1, 3, 1.
Why NOT to Add Thiazolidinedione
Adding a thiazolidinedione (TZD) instead of continuing insulin would be inappropriate:
TZDs have slow onset of action (weeks to months for full effect) and cannot provide the immediate glycemic control needed post-DKA.
TZDs are not recommended as initial therapy after DKA. The guidelines prioritize GLP-1 receptor agonists or SGLT2 inhibitors as add-on agents to metformin and insulin when additional therapy is needed 1, 3, 1.
TZDs cause weight gain and fluid retention, which may worsen patient acceptance and are contraindicated in heart failure.
Addressing Patient Hesitancy
Patient education is critical here. The AACE guidelines emphasize that "clinicians should discuss with persons with T2D the likelihood that most persons with T2D ultimately require a combination of multiple complementary antihyperglycemic agents, in addition to lifestyle interventions" 1.
Key counseling points:
- DKA is life-threatening and indicates severe insulin deficiency that metformin alone cannot address
- Insulin prevents recurrent DKA and serious complications including death
- The dose is modest (10 units glargine is a low starting dose per FDA labeling 4)
- Hypoglycemia risk is low with basal insulin alone when properly dosed
- This may not be permanent—glycemic control can be reassessed after 3 months, and therapy adjusted based on A1C and glucose monitoring 1
Future Considerations
Once metabolic stability is achieved (typically 3 months), consider:
- Adding a GLP-1 receptor agonist if A1C remains elevated, as these are preferred over TZDs for intensification 1
- Adding an SGLT2 inhibitor if cardiovascular or renal comorbidities exist 1
- Titrating insulin based on fasting glucose targets
Critical pitfall to avoid: Do NOT discontinue insulin prematurely in a patient who presented with DKA. The anion gap closure does not mean the underlying severe hyperglycemia is resolved—it only means the acute ketoacidosis has been corrected. Basal insulin remains essential to prevent recurrence.